Pause, Not Rewind
Pause, Not Rewind
COVID-19 Has Slowed or Halted HIV Studies, But Research Must Continue
by Jeannie Wraight
F
or most of the U.S. and all but a few...
Expediting Research
GlaxoSmithKline (GSK) and the University of North Carolina at Chapel-Hill (UNC) will launch a jointly owned novel HIV Cure Center, as well as a...
IV Drug Users & HIV Vaccine Response
Everyone Counts
Differences in intravenous drug users may affect their response to an HIV vaccine
by Jeannie Wraight
Prevention strategies such as Treatment as Prevention, PrEP, syringe...
Talking “Cure”
Nobel Prize Laureate and world renowned HIV researcher Françoise Barré-Sinoussi recently made the statement that she does not believe an HIV cure is possible....
APPROACH Study
Mosaic Design
APPROACH, a preventive vaccine study, seeks to address more than one clade
by Jeannie Wraight
Over the past thirty-plus years, strategies such as Treatment as...
Countdown to a Cure
by Jeannie Wraight
As part of the Countdown to a Cure Initiative, amfAR (The Foundation for AIDS Research) will direct $20 million, of a $100...
Questioning the Cure
When first discussing the potential of writing a monthly column on HIV cure, my editor here at A&U Magazine asked a very valid question....
Targeting HIV Reservoirs
Hiding Place
One focus of the amfAR 2016 CURE Summit targeted HIV reservoirs
by Jeannie Wraight
This year, amfAR marked World AIDS Day with the 2016 HIV...
David Evans
Risk & Reward
Activist David Evans weighs in on next steps in cure advocacy & research
by Jeannie Wraight
In the late 1980s and throughout the ’90s,...
BIT225: HIV VPU Inhibitor Candidate
Contender in the Ring
A novel HIV therapy targets & eradicates one cell type in the viral reservoir
by Jeannie Wraight
BIT225, an HIV VPU inhibitor, has...
LATEST POSTS
$210M Funding Opportunity for CBOs
CDC Announces $210M Funding Opportunity for CBOs
On September 28, 2020, the Centers for Disease Control and Prevention (CDC) announced the availability in fiscal 2021...
